Imaging tumor hypoxia by magnetic resonance methods

NMR in Biomedicine

Volumn 24, Issue 1, 2011, Pages 1-16

  Pacheco Torres, Jesús ^a,b   López Larrubia, Pilar ^a   Ballesteros, Paloma ^b   Cerdán, Sebastián ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b UNIVERSIDAD A DISTANCIA DE MADRID   (Spain)

Author keywords

19F NMR probes; 1H NMR probes; EPR probes; Nitroimidazole; NMR oximetry; Tumor diagnosis

Indexed keywords

EPR PROBES; NITROIMIDAZOLES; NMR PROBE; OXIMETRY; TUMOR DIAGNOSIS;

DIAGNOSIS; ELECTRON SPIN RESONANCE SPECTROSCOPY; MAGNETIC SUSCEPTIBILITY; NUCLEAR MAGNETIC RESONANCE; OXYGEN; PARAMAGNETIC MATERIALS; PARAMAGNETISM; PROBES; RELAXATION PROCESSES; RESONANCE; SPIN DYNAMICS; TRANSCRIPTION FACTORS;

TUMORS;

DEOXYHEMOGLOBIN; FLUOROCARBON; HYPOXIA INDUCIBLE FACTOR; NITROIMIDAZOLE; OXYGEN; OXYHEMOGLOBIN; TRANSCRIPTION FACTOR;

CANCER INVASION; CELL TRANSFORMATION; ELECTRON SPIN RESONANCE; HEMODYNAMICS; HUMAN; HYPOXIA; MAGNETISM; METASTASIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN TENSION; PLEIOTROPY; PRIORITY JOURNAL; RELAXATION TIME; REVIEW; TUMOR;

ANIMALS; BIOLOGICAL MARKERS; CELL HYPOXIA; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS;

RATTUS;

EID: 78851471290     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1558     Document Type: Review

References (146)

1. Emsley J. Oxygen. Nature's Building Blocks: An A-Z Guide to the Elements. Oxford University Press: Oxford, 2001; 297-304.
2. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, Hill RP, Koch CJ, Krishna MC, Krohn KA, Lewis JS, Mason RP, Melillo G, Padhani AR, Powis G, Rajendran JG, Reba R, Robinson SP, Semenza GL, Swartz HM, Vaupel P, Yang D, Croft B, Hoffman J, Liu G, Stone H, Sullivan D. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int. J. Radiat. Biol. 2006; 82(10): 699-757.
3. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 1953; 26(312): 638-648.
4. Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, Broder GJ. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 1988; 14(5): 831-838.
5. Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett. 2003; 195(1): 1-16.
6. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, Terris DJ, Overgaard J. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother. Oncol. 2005; 77(1): 18-24.
7. Pijnenborg JM, Wijnakker M, Hagelstein J, Delvoux B, Groothuis PG. Hypoxia contributes to development of recurrent endometrial carcinoma. Int. J. Gynecol. Cancer, 2007; 17(4): 897-904.
8. Vaupel P, Mayer A, Briest S, Hockel M. Hypoxia in breast cancer: role of blood flow, oxygen diffusion distances, and anemia in the development of oxygen depletion. Adv. Exp. Med. Biol. 2005; 566: 333-342.
9. Greco O, Scott S. Tumor hypoxia and targeted gene therapy. Int. Rev. Cytol. 2007; 257: 181-212.
10. Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist, 2004; 9(Suppl 5): 31-40.
11. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist, 2004; 9(Suppl 5): 4-9.
12. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996; 56(19): 4509-4515.
13. Vaupel P, Mayer A, Hockel M. Tumor hypoxia and malignant progression. Methods Enzymol. 2004; 381: 335-354.
14. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 2001; 93(4): 266-276.
15. Charnley N, Donaldson S, Price P. Imaging angiogenesis. Methods Mol Biol 2009; 467: 25-51.
16. Ross BD, Moffat BA, Lawrence TS, Mukherji SK, Gebarski SS, Quint DJ, Johnson TD, Junck L, Robertson PL, Muraszko KM, Dong Q, Meyer CR, Bland PH, McConville P, Geng H, Rehemtulla A, Chenevert TL. Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther. 2003; 2(6): 581-587.
17. Moffat BA, Chenevert TL, Meyer CR, McKeever PE, Hall DE, Hoff BA, Johnson TD, Rehemtulla A, Ross BD. The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia, 2006; 8(4): 259-267.
18. Jordan BF, Runquist M, Raghunand N, Baker A, Williams R, Kirkpatrick L, Powis G, Gillies RJ. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia, 2005; 7(5): 475-485.
19. Griffiths JR, Robinson SP. The OxyLite: a fibre-optic oxygen sensor. Br. J. Radiol. 1999; 72(859): 627-630.
20. Vaupel P, Hockel M, Mayer A. Detection and characterization of tumor hypoxia using pO(2) histography. Antioxid. Redox Signal. 2007; 9: 1221-1236.
21. Foo SS, Abbott DF, Lawrentschuk N, Scott AM. Functional imaging of intratumoral hypoxia. Mol. Imaging Biol. 2004; 6(5): 291-305.
22. Padhani AR, Krohn KA, Lewis JS, Alber M. Imaging oxygenation of human tumours. Eur. Radiol. 2007; 17(4): 861-872.
23. Vikram DS, Zweier JL, Kuppusamy P. Methods for noninvasive imaging of tissue hypoxia. Antioxid. Redox Signal. 2007; 9(10): 1745-1756.
24. Ljungkvist AS, Bussink J, Kaanders JH, van der Kogel AJ. Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. Radiat. Res. 2007; 167(2): 127-145.
25. Liu H, Gu Y, Kim JG, Mason RP. Near infrared spectroscopy and imaging of tumor vascular oxygenation. Methods Enzymol. 2004; 386: 349-378.
26. Moeller BJ, Cao Y, Vujaskovic Z, Li CY, Haroon ZA, Dewhirst MW. The relationship between hypoxia and angiogenesis. Semin. Radiat. Oncol. 2004; 14(3): 215-221.
27. Hickey MM, Simon MC. Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Curr. Top. Dev. Biol. 2006; 76: 217-257.
28. Nilsson H, Jogi A, Beckman S, Harris AL, Poellinger L, Pahlman S. HIF-2alpha expression in human fetal paraganglia and neuroblastoma: relation to sympathetic differentiation, glucose deficiency, and hypoxia. Exp. Cell Res. 2005; 303(2): 447-456.
29. Gallez B, Baudelet C, Jordan BF. Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications. NMR Biomed. 2004; 17(5): 240-262.
30. Munn LL. Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov. Today, 2003; 8(9): 396-403.
31. Menon C, Fraker DL. Tumor oxygenation status as a prognostic marker. Cancer Lett. 2005; 221(2): 225-235.
32. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin. Oncol. 2001; 28 (2 Suppl 8): 29-35.
33. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem. Sci. 1999; 24(2): 68-72.
34. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell, 2003; 3(4): 347-361.
35. Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 2007; 67(2): 563-572.
36. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 1996; 379(6560): 88-91.
37. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer, 2002; 2(1): 38-47.
38. Seimiya H, Tanji M, Oh-hara T, Tomida A, Naasani I, Tsuruo T. Hypoxia up-regulates telomerase activity via mitogen-activated protein kinase signaling in human solid tumor cells. Biochem. Biophys. Res. Commun. 1999; 260(2): 365-370.
39. Semenza GL. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 2003; 3(10): 721-732.
40. Helczynska K, Kronblad A, Jogi A, Nilsson E, Beckman S, Landberg G, Pahlman S. Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res. 2003; 63(7): 1441-1444.
41. Clottes E. Hypoxia-inducible factor 1: regulation, involvement in carcinogenesis and target for anticancer therapy. Bull. Cancer, 2005; 92(2): 119-127.
42. Maxwell PH. The HIF pathway in cancer. Semin. Cell Dev. Biol. 2005; 16(4-5): 523-530.
43. Shi YH, Fang WG. Hypoxia-inducible factor-1 in tumour angiogenesis. World J. Gastroenterol. 2004; 10(8): 1082-1087.
44. Ruas JL, Poellinger L. Hypoxia-dependent activation of HIF into a transcriptional regulator. Semin. Cell Dev. Biol. 2005; 16(4-5): 514-522.
45. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature, 2006; 441(7092): 437-443.
46. Fels DR, Koumenis C. The PERK/eIF2alpha/ATF4 module of the UPR in hypoxia resistance and tumor growth. Cancer Biol. Ther. 2006; 5(7): 723-728.
47. Wouters BG, van den BT, Magagnin MG, Koritzinsky M, Fels D, Koumenis C. Control of the hypoxic response through regulation of mRNA translation. Semin. Cell Dev. Biol. 2005; 16(4-5): 487-501.
48. Blouw B, Song H, Tihan T, Bosze J, Ferrara N, Gerber HP, Johnson RS, Bergers G. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell, 2003; 4(2): 133-146.
49. Stephen RN, Gillies RJ. Promise and progress for functional and molecular imaging response to targetted therapies. Pharm. Res. 2007; 24(6): 1172-1185.
50. Hockel M, Schlenger K, Hockel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 1999; 59(18): 4525-4528.
51. Mason RP, Ran S, Thorpe PE. Quantitative assessment of tumor oxygen dynamics: molecular imaging for prognostic radiology. J. Cell Biochem. Suppl. 2002; 39: 45-53.
52. Pitson G, Fyles A, Milosevic M, Wylie J, Pintilie M, Hill R. Tumor size and oxygenation are independent predictors of nodal diseases in patients with cervix cancer. Int. J. Radiat. Oncol. Biol. Phys. 2001; 51(3): 699-703.
53. Olive PL, Banath JP, Quino-Parsons C. Measuring hypoxia in solid tumours - is there a gold standard? Acta Oncol. 2001; 40(8): 917-923.
54. Evans SM, Judy KD, Dunphy I, Jenkins WT, Nelson PT, Collins R, Wileyto EP, Jenkins K, Hahn SM, Stevens CW, Judkins AR, Phillips P, Geoerger B, Koch CJ. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res. 2004; 64(5): 1886-1892.
55. Le QT, Koong A, Lieskovsky YY, Narasimhan B, Graves E, Pinto H, Brown JM, Spielman D. In vivo 1H magnetic resonance spectroscopy of lactate in patients with stage IV head and neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2008; 71(4): 1151-1157.
56. Negendank WG, Padavic-Shaller KA, Li CW, Murphy-Boesch J, Stoyanova R, Krigel RL, Schilder RJ, Smith MR, Brown TR. Metabolic characterization of human non-Hodgkin's lymphomas in vivo with the use of proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res. 1995; 55(15): 3286-3294.
57. Li CW, Kuesel AC, Padavic-Shaller KA, Murphy-Boesch J, Eisenberg BL, Schmidt RG, von Roemeling RW, Patchefsky AS, Brown TR, Negendank WG. Metabolic characterization of human soft tissue sarcomas in vivo and in vitro using proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res. 1996; 56(13): 2964-2972.
58. 31P NMR spectroscopy: correlation with tumor progression. Exp. Oncol. 2007; 29(3): 207-211.
59. 19F magnetic resonance imaging of perfluorocarbons. Curr. Sci. 1999; 76(6): 753-762.
60. Parhami P, Fung BM. Fluorine-19 relaxation study of perfluoro chemicals as oxygen carriers. J. Phys. Chem. 1983; 87: 1928-1931.
61. Lewa CJ, Majewska Z. Temperature relationships of proton spin-lattice relaxation time T1 in biological tissues. Bull. Cancer, 1980; 67(5): 35.
62. Zhao D, Jiang L, Mason RP. Measuring changes in tumor oxygenation. Methods Enzymol. 2004; 386: 378-418.
63. 1H NMR approach to quantitative tissue oximetry using hexamethyldisiloxane. Magn. Reson. Med. 2006; 55(4): 743-748.
64. 19F signals from perfluorocarbon nanoparticles as a new strategy for molecular imaging. Magn. Reson. Med. 2008; 60(5): 1066-1072.
65. Thomas SR, Pratt RG, Millard RW, Samaratunga RC, Shiferaw Y, Clark LC, Hoffmann RE. Evaluation of the influence of the aqueous phase bioconstituent environment on the F-19 T1 of perfluorocarbon blood substitute emulsions. J. Magn. Reson. Imaging, 1994; 4(4): 631-635.
66. Kodibagkar VD, Wang X, Mason RP. Physical principles of quantitative nuclear magnetic resonance oximetry. Front. Biosci. 2008; 13: 1371-1384.
67. 19F NMR spectroscopy of perfluorocarbon. Magn. Reson. Med. 1993; 29: 296-302.
68. 19F MR EPI and electrodes. Adv. Exp. Med. Biol. 2003; 530: 19-27.
69. 19F magnetic resonance imaging: simultaneous comparison with fluorescence quenching. Magn. Reson. Med. 2009; 61(3): 634-638.
70. 19F nuclear magnetic resonance methodologies for the assessment of tumour hypoxia. Philos. Trans. R. Soc. London, B: Biol. Sci. 2004; 359(1446): 987-996.
71. 19F NMR of perfluorocarbons. Artif. Cells Blood Substit. Immobil. Biotechnol. 1994; 22(4): 1141-1153.
72. 19F MRI study of tumor bearing mice. Magn. Reson. Imaging, 1989; 7(5): 475-485.
73. Mason RP, Antich PP, Babcock EE, Constantinescu A, Peschke P, Hanhn EW. Non invasive determination of tumor oxygen tension and local variation with growth. Int. J. Radiat. Oncol. Biol. Phys. 1994; 29(1): 95-103.
74. 19F NMR indicator of tumor oxygenation. NMR Biomed. 1996; 9(3): 125-134.
75. 19F-NMR imaging. Adv. Exp. Med. Biol. 1994; 361: 129-134.
76. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J. Nucl. Med. 2008; 49 (Suppl 2): 129S-148S.
77. 15C5-loaded alginate capsules as fluorine-19 magnetic resonance imaging oxygen sensors. Int. J. Radiat. Oncol. Biol. Phys. 2004; 60(3): 909-919.
78. Hunjan S, Zhao D, Constantinescu A, Hahn EW, Antich PP, Mason RP. Tumor oximetry: demonstration of an enhanced dynamic mapping procedure using fluorine-19 echo planar magnetic resonance imaging in the Dunning prostate R3327-AT1 rat tumor. Int. J. Radiat. Oncol. Biol. Phys. 2001; 49(4): 1097-1108.
79. Zhao D, Constantinescu A, Jiang L, Hahn EW, Mason RP. Prognostic radiology: quantitative assessment of tumor oxygen dynamics by MRI. Am. J. Clin. Oncol. 2001; 24(5): 462-466.
80. Zhao D, Constantinescu A, Hahn EW, Mason RP. Differential oxygen dynamics in two diverse Dunning prostate R3327 rat tumor sublines (MAT-Lu and HI) with respect to growth and respiratory challenge. Int. J. Radiat. Oncol. Biol. Phys. 2002; 53(3): 744-756.
81. Zhao D, Ran S, Constantinescu A, Hahn E, Mason R. Tumor oxygen dynamics: correlation of in vivo MRI with histological findings. Neoplasia, 2003; 5(4): 308-318.
82. Pacheco-Torres J, Zhao D, Kodibagkar V, Contero A, Saha D, Mason RP. More FREDOM: evaluation of lung tumor oxygenation in rats. Proceedings of the 16th Annual Meeting ISMRM, Toronto, Canada, 2008; 5339.
83. Zhao D, Constantinescu A, Chang CH, Hahn EW, Mason RP. Correlation of tumor oxygen dynamics with radiation response of the Dunning prostate R3327-HI tumor. Radiat. Res. 2003; 159(5): 621-631.
84. Bourke VA, Zhao D, Gilio J, Chang CH, Jiang L, Hanh EW, Mason RP. Correlation of radiation response with tumor oxygenation in the Dunning Prostate R3327-AT1 tumor. Int. J. Radiat. Oncol. Biol. Phys. 2007; 67: 1179-1186.
85. 19F inversion-recovery echo-planar imaging of perfluoro-15-crown-5-ether. Magn. Reson. Med. 1994; 32(1): 88-97.
86. Kodibagkar VD, Wang X, Pacheco-Torres J, Gulaka P, Mason RP. Proton imaging of siloxanes to map tissue oxygenation levels (PISTOL): a tool for quantitative tissue oximetry. NMR Biomed. 2008; 21(8): 899-907.
87. Ndubuizu O, La Manna JC. Brain tissue oxygen concentration measurements. Antioxid. Redox Signal. 2007; 9(8): 1207-1219.
88. Karczmar GS, River JN, Li J, Vijayakumar S, Goldman Z, Lewis MZ. Effects of hyperoxia on T2 and resonance frequency weighted magnetic resonance images of rodent tumours. NMR Biomed. 1994; 7(1-2): 3-11.
89. Robinson SP, Howe FA, Griffiths JR. Noninvasive monitoring of carbogen-induced changes in tumor blood flow and oxygenation by functional magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys. 1995; 33(4): 855-859.
90. Rodrigues L, Howe F, Griffiths J, Robinson S. Tumor R2 is a prognostic indicator of acute radiotherapeutic response in rodent tumors. J. Magn. Reson. Imaging, 2004; 19(4): 482-488.
91. Baudelet C, Gallez B. How does blood oxygen level-dependent (BOLD) contrast correlate with oxygen partial pressure (pO2) inside tumors? Magn. Reson. Med. 2002; 48(6): 980-986.
92. Jordan BF, Crokart N, Baudelet C, Cron GO, Ansiaux R, Gallez B. Complex relationship between changes in oxygenation status and changes in R2: the case of insulin and NS-398, two inhibitors of oxygen consumption. Magn. Reson. Med. 2006; 56(3): 637-643.
93. Howe FA, Robinson SP, McIntyre DJ, Stubbs M, Griffiths JR. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed. 2001; 14(7-8): 497-506.
94. Alonzi R, Padhani AR, Maxwell RJ, Taylor NJ, Stirling JJ, Wilson JI, d'Arcy JA, Collins DJ, Saunders MI, Hoskin PJ. Carbogen breathing increases prostate cancer oxygenation: a translational MRI study in murine xenografts and humans. Br. J. Cancer, 2009; 100(4): 644-648.
95. Rijpkema M, Kaanders JH, Joosten FB, van der Kogel AJ, Heerschap A. Effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and vascularity of head-and-neck tumors as measured by magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys. 2002; 53(5): 1185-1191.
96. Taylor NJ, Baddeley H, Goodchild KA, Powell ME, Thoumine M, Culver LA, Stirling JJ, Saunders MI, Hoskin PJ, Phillips H, Padhani AR, Griffiths JR. BOLD MRI of human tumor oxygenation during carbogen breathing. J. Magn. Reson. Imaging, 2001; 14(2): 156-163.
97. Matsumoto K, Bernardo M, Subramanian S, Choyke P, Mitchell JB, Krishna MC, Lizak MJ. MR assessment of changes of tumor in response to hyperbaric oxygen treatment. Magn. Reson. Med. 2006; 56(2): 240-246.
98. 1H MRI. Proceedings of the 16th Annual Meeting ISMRM, Toronto, Canada, 2008; 4337.
99. O'Connor JP, Jackson A, Buonaccorsi GA, Buckley DL, Roberts C, Watson Y, Cheung S, McGrath DM, Naish JH, Rose CJ, Dark PM, Jayson GC, Parker GJ. Organ-specific effects of oxygen and carbogen gas inhalation on tissue longitudinal relaxation times. Magn. Reson. Med. 2007; 58(3): 490-496.
100. O'Connor JP, Naish JH, Jackson A, Waterton JC, Watson Y, Cheung S, Buckley DL, McGrath DM, Buonaccorsi GA, Mills SJ, Roberts C, Jayson GC, Parker GJ. Comparison of normal tissue R1 and R2 modulation by oxygen and carbogen. Magn. Reson. Med. 2009; 61(1): 75-83.
101. O'Connor JPB, Naish J, Parker GJM, Waterton J, Watson Y, Jayson G, Buonaccorsi G, Cheung S, Buckley D, McGrath D, West CML, Davidson S, Roberts C, Mills S, Mitchell C, Hope L, Ton NC, Jackson A. Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumors. Int. J. Radiat. Oncol. Biol. Phys. 2009; 75(4): 1209-1215.
102. Declerck PJ, Ranter CJ. Electron requirements in nitroimidazole reduction. Analusis, 1987; 15(3): 148-150.
103. Whitmore GF, Varghese AJ. The biological properties of reduced nitroheterocyclics and possible underlying biochemical mechanisms. Biochem. Pharmacol. 1986; 35(1): 97-103.
104. Knox RJ, Knight RC, Edwards DI. Studies on the action of nitroimidazole drugs. The products of nitroimidazole reduction. Biochem. Pharmacol. 1983; 32(14): 2149-2156.
105. Krause BJ, Beck R, Souvatzoglou M, Piert M. PET and PET/CT studies of tumor tissue oxygenation. Q.J. Nucl. Med. Mol. Imaging, 2006; 50(1): 28-43.
106. Janssen HL, Haustermans KM, Balm AJ, Begg AC. Hypoxia in head and neck cancer: how much, how important? Head Neck, 2005; 27(7): 622-638.
107. Varghese AJ, Gulyas S, Mohindra JK. Hypoxia-dependent reduction of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo. Cancer Res. 1976; 36(10): 3761-3765.
108. Brezden CB, Horn L, McClelland RA, Rauth AM. Oxidative stress and 1-methyl-2-nitroimidazole cytotoxicity. Biochem. Pharmacol. 1998; 56(3): 335-344.
109. Varghese AJ, Whitmore GF. Properties of 2-hydroxylaminoimidazoles and their implications for the biological effects of 2-nitroimidazoles. Chem. Biol. Interact. 1985; 56(2-3): 269-287.
110. Bolton JL, McClelland RA. Kinetics and mechanism of the decomposition in aqueous solutions of 2-(hydroxyamino)imidazoles. J. Am. Chem. Soc. 1989; 111(21): 8172-8181.
111. Joseph P, Jaiswal AK, Stobbe CC, Chapman JD. The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles. Int. J. Radiat. Oncol. Biol. Phys. 1994; 29(2): 351-355.
112. Aboagye EO, Lewis AD, Tracy M, Workman P. Bioreductive metabolism of the novel fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3, 3, 3-trifluoropropyl)-2-(2-nitroimidazolyl) acetamide (SR-4554). Biochem. Pharmacol. 1997; 54(11): 1217-1224.
113. Mahy P, De BM, Gallez B, Gueulette J, Koch CJ, Scalliet P, Gregoire V. In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors. Radiother. Oncol. 2003; 67(1): 53-61.
114. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother. Oncol. 1998; 46(3): 229-237.
115. Koch CJ. Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Methods Enzymol. 2002; 352: 3-31.
116. Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more important than the 'hypoxic fraction' in determining tumor response to fractionated radiotherapy. Radiat. Res. 1997; 147(5): 541-550.
117. 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors. Radiother. Oncol. 2004; 73(3): 359-366.
118. Hoff MN, Yapp DT, Yung AC, Oliver TS, Kozlowski P. In vivo measurement of the hypoxia marker EF5 in Shionogi tumours using (19)F magnetic resonance spectroscopy. Int. J. Radiat. Biol. 2008; 84(3): 237-242.
119. Seddon BM, Workman P. The role of functional and molecular imaging in cancer drug discovery and development. Br. J. Radiol. 2003; 76 (Spec No 2): S128-S138.
120. Aboagye EO, Maxwell RJ, Horsman MR, Lewis AD, Workman P, Tracy M, Griffiths JR. The relationship between tumour oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554. Br. J. Cancer, 1998; 77(1): 65-70.
121. Raleigh JA, Franko AJ, Treiber EO, Lunt JA, Allen PS. Covalent binding of a fluorinated 2-nitroimidazole to EMT-6 tumors in Balb/C mice: detection by F-19 nuclear magnetic resonance at 2.35T. Int. J. Radiat. Oncol. Biol. Phys. 1986; 12(7): 1243-1245.
122. Maxwell RJ, Workman P, Griffiths JR. Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo. Int. J. Radiat. Oncol. Biol. Phys. 1989; 16(4): 925-929.
123. 19F magnetic resonance method for measuring oxygen deficiency in tumors. Magn. Reson. Med. 1991; 22(2): 451-466.
124. Aboagye EO, Maxwell RJ, Kelson AB, Tracy M, Lewis AD, Graham MA, Horsman MR, Griffiths JR, Workman P. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3, 3, 3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia. Cancer Res. 1997; 57(15): 3314-3318.
125. Aboagye EO, Lewis AD, Graham MA, Tracy M, Kelson AB, Ryan KJ, Workman P. The pharmacokinetics, bioavailability and biodistribution in mice of a rationally designed 2-nitroimidazole hypoxia probe SR-4554. Anticancer Drug Des. 1996; 11(3): 231-242.
126. Seddon BM, Maxwell RJ, Honess DJ, Grimshaw R, Raynaud F, Tozer GM, Workman P. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. Clin. Cancer Res. 2002; 8(7): 2323-2335.
127. Seddon BM, Payne GS, Simmons L, Ruddle R, Grimshaw R, Tan S, Turner A, Raynaud F, Halbert G, Leach MO, Judson I, Workman P. A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clin. Cancer Res. 2003; 9(14): 5101-5112.
128. Lee CP, Payne GS, Oregioni A, Ruddle R, Tan S, Raynaud FI, Eaton D, Campbell MJ, Cross K, Halbert G, Tracy M, McNamara J, Seddon B, Leach MO, Workman P, Judson I. A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy. Br. J. Cancer 2009; 101(11): 1860-1868.
129. 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors. Clin. Cancer Res. 2007; 13(12): 3738-3747.
130. Pacheco-Torres J, Perez-Mayoral E, Ouari O, Gonzales-Cortes A, Cerdan S, Ballesteros P. A convenient and efficient synthesis of the first (nitroimidazolyl)succinic esters and their diacids. Synthesis, 2006; 22: 3859-3864.
131. Khan N, Williams BB, Hou H, Li H, Swartz HM. Repetitive tissue pO(2) measurements by electron paramagnetic resonance oximetry: current status and future potential for experimental and clinical studies. Antioxid. Redox Signal. 2007; 9(8): 1169-1182.
132. Swartz HM, Khan N, Buckey J, Comi R, Gould L, Grinberg O, Hartford A, Hopf H, Hou H, Hug E, Iwasaki A, Lesniewski P, Salikhov I, Walczak T. Clinical applications of EPR: overview and perspectives. NMR Biomed. 2004; 17(5): 335-351.
133. 2 measurements by electron paramagnetic resonance oximetry. Radiat. Res. 1998; 150(5): 549-556.
134. Matsumoto S, Espey MG, Utsumi H, Devasahayam N, Matsumoto KI, Matsumoto A, Hirata H, Wink DA, Kuppusamy P, Subramanian S, Mitchell JB, Krishna MC. Dynamic monitoring of localized tumor oxygenation changes using RF pulsed electron paramagnetic resonance in conscious mice. Magn. Reson. Med. 2008; 59(3): 619-625.
135. Bratasz A, Pandian RP, Deng Y, Petryakov S, Grecula JC, Gupta N, Kuppusamy P. In vivo imaging of changes in tumor oxygenation during growth and after treatment. Magn. Reson. Med. 2007; 57(5): 950-959.
136. Elas M, Williams B, Parasca A, Mailer C, Pelizzari C, Lewis M, River J, Karczmar G, Barth E, Halpern H. Quantitative tumor oximetric images from 4D electron paramagnetic resonance imaging (EPRI): methodology and comparison with blood oxygen level-dependent (BOLD) MRI. Magn. Reson. Med. 2003; 49(4): 682-691.
137. Ardenkjaer-Larsen JH, Laursen I, Leunbach I, Ehnholm G, Wistrand LG, Petersson JS, Golman K. EPR and DNP properties of certain novel single electron contrast agents intended for oximetric imaging. J. Magn. Reson. 1998; 133(1): 1-12.
138. Golman K, Petersson JS, Rdenkjaer-Larsen JH, Leunbach I, Wistrand LG, Ehnholm G, Liu K. Dynamic in vivo oximetry using overhauser enhanced MR imaging. J. Magn. Reson. Imaging, 2000; 12(6): 929-938.
139. Krishna MC, English S, Yamada K, Yoo J, Murugesan R, Devasahayam N, Cook JA, Golman K, Rdenkjaer-Larsen JH, Subramanian S, Mitchell JB. Overhauser enhanced magnetic resonance imaging for tumor oximetry: coregistration of tumor anatomy and tissue oxygen concentration. Proc. Natl. Acad. Sci. USA, 2002; 99(4): 2216-2221.
140. Vaupel P, Mayer A, Briest S, Hockel M. Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res. 2003; 63(22): 7634-7637.
141. Vaupel P, Hockel M, Mayer A. Detection and Characterization of Tumor Hypoxia Using pO(2) Histography. Antioxid. Redox Signal. 2007.
142. Ziemer LS, Lee WM, Vinogradov SA, Sehgal C, Wilson DF. Oxygen distribution in murine tumors: characterization using oxygen-dependent quenching of phosphorescence. J. Appl. Physiol. 2005; 98(4): 1503-1510.
143. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996; 56(5): 941-943.
144. Brizel DM, Rosner GL, Prosnitz LR, Dewhirst MW. Patterns and variability of tumor oxygenation in human soft tissue sarcomas, cervical carcinomas, and lymph node metastases. Int. J. Radiat. Oncol. Biol. Phys. 1995; 32(4): 1121-1125.
145. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother. Oncol. 1999; 53(2): 113-117.
146. 2 protect HepG2 cells against serum deprivation- and t-BHP-induced apoptosis: a possible anti-apoptotic role for HIF-1. Exp. Cell Res. 2004; 295(2): 340-349.